Covid vaccines IP waiver is 'in direct response to an emergency': Ramaphosa

South African President Cyril Ramaphosa has dedicated his weekly letter to the nation to the issue of waiving intellectual property rights on Covid-19 vaccines, saying it's necessary at this time

Topics
Coronavirus Vaccine | intellectual property rights | Cyril Ramaphosa

AP  |  Cape Town 

Cyril Ramaphosa
South African President Cyril Ramaphosa

South African President has dedicated his weekly letter to the nation to the issue of waiving on COVID-19 vaccines, saying it's necessary at this time and in direct response to an emergency.

Ramaphosa's message reflects his country's hope that the waiver, first proposed by South Africa and India, may still happen despite opposition from nations like Germany.

Ramaphosa writes that the Biden Administration's support for a waiver has given negotiations at the World Trade Organisation added momentum. He compares the vaccine IP waiver issue to South Africa's eventually successful fight two decades ago to ease IPs on life-saving antiretroviral drugs during the HIV/Aids crisis.

And once again, South Africa is waging a struggle that puts global solidarity to the test, Ramaphosa wrote.

European Union leaders have doubted the immediate benefit of a waiver of IPs on COVID-19 vaccines, saying many less developed countries, particularly in Africa, don't have the capacity to manufacture vaccines even if the waiver is achieved.

Ramaphosa writes that South Africa is one of five countries in Africa with vaccine production capacity and a waiver would enable them to bolster global vaccine manufacturing for COVID-19 and other major diseases.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Tue, May 11 2021. 06:45 IST
RECOMMENDED FOR YOU